• Consensus Rating: Buy
  • Consensus Price Target: $16.00
  • Forecasted Upside: 607.96 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$2.26
▲ +0.06 (2.73%)

This chart shows the closing price for BCEL by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Atreca Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BCEL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BCEL

Analyst Price Target is $16.00
▲ +607.96% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Atreca in the last 3 months. The average price target is $16.00, with a high forecast of $25.00 and a low forecast of $9.00. The average price target represents a 607.96% upside from the last price of $2.26.

This chart shows the closing price for BCEL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 polled investment analysts is to buy stock in Atreca. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/24/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/25/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/23/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/21/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/19/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/20/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/19/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/18/2022

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/8/2022Brookline Capital ManagementReiterated RatingBuyLow
5/19/2022Robert W. BairdLower Target$12.00 ➝ $9.00High
4/6/2022HC WainwrightReiterated RatingBuy$25.00Medium
3/4/2022WedbushReiterated RatingOutperformHigh
3/4/2022HC WainwrightReiterated RatingBuy$25.00High
3/4/2022Stifel NicolausLower TargetBuy$17.00 ➝ $14.00High
7/30/2021WedbushLower TargetOutperform$27.00 ➝ $12.00High
7/29/2021Brookline Capital ManagementReiterated RatingBuyHigh
7/29/2021Stifel NicolausBoost TargetBuy$17.00 ➝ $31.00High
7/27/2021HC WainwrightReiterated RatingBuy$25.00Low
7/1/2021Jefferies Financial GroupReiterated RatingBuy$30.00High
2/8/2021Jefferies Financial GroupInitiated CoverageBuy$30.00High
8/12/2020HC WainwrightLower TargetBuy$30.00 ➝ $25.00High
7/8/2020HC WainwrightReiterated RatingBuy$30.00Medium
6/17/2020CowenReiterated RatingBuyHigh
6/16/2020HC WainwrightReiterated RatingBuy$30.00High
6/10/2020HC WainwrightReiterated RatingBuy$30.00High
5/15/2020HC WainwrightReiterated RatingBuy$30.00High
4/22/2020HC WainwrightInitiated CoverageBuy$30.00High
4/21/2020WedbushInitiated CoverageOutperform$27.00High
4/15/2020Robert W. BairdInitiated CoverageOutperform$30.00High
9/4/2019Roth CapitalInitiated CoverageBuy$30.00High
8/20/2019Brookline Capital ManagementReiterated RatingBuyHigh
8/14/2019CowenReiterated RatingBuyHigh
7/15/2019Stifel NicolausInitiated CoverageBuy ➝ Buy$28.00Low
7/15/2019Evercore ISIInitiated CoverageOutperform ➝ Outperform$16.63Low
7/15/2019CowenInitiated CoverageOutperform ➝ OutperformLow
(Data available from 8/18/2017 forward)

News Sentiment Rating

0.36 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/20/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
2/19/2022
  • 3 very positive mentions
  • 8 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
3/21/2022
  • 2 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
4/20/2022
  • 3 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/20/2022
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/19/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
7/19/2022
  • 3 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/18/2022

Current Sentiment

  • 3 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Atreca logo
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients. It also developing APN-122597, a receptor tyrosine kinase that target tumor tissues; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. Atreca, Inc. was incorporated in 2010 and is based in San Carlos, California.
Read More

Today's Range

Now: $2.26
Low: $2.21
High: $2.64

50 Day Range

MA: $2.08
Low: $1.67
High: $2.74

52 Week Range

Now: $2.26
Low: $1.51
High: $7.00

Volume

916 shs

Average Volume

160,239 shs

Market Capitalization

$85.34 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.69

Frequently Asked Questions

What sell-side analysts currently cover shares of Atreca?

The following sell-side analysts have issued reports on Atreca in the last twelve months: Brookline Capital Management, HC Wainwright, Robert W. Baird, Stifel Nicolaus, and Wedbush.
View the latest analyst ratings for BCEL.

What is the current price target for Atreca?

3 Wall Street analysts have set twelve-month price targets for Atreca in the last year. Their average twelve-month price target is $16.00, suggesting a possible upside of 608.0%. HC Wainwright has the highest price target set, predicting BCEL will reach $25.00 in the next twelve months. Robert W. Baird has the lowest price target set, forecasting a price of $9.00 for Atreca in the next year.
View the latest price targets for BCEL.

What is the current consensus analyst rating for Atreca?

Atreca currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BCEL will outperform the market and that investors should add to their positions of Atreca.
View the latest ratings for BCEL.

What other companies compete with Atreca?

How do I contact Atreca's investor relations team?

Atreca's physical mailing address is 500 SAGINAW DRIVE FIRST FLOOR, REDWOOD CITY CA, 94063. The company's listed phone number is (650) 595-2595 and its investor relations email address is [email protected] The official website for Atreca is www.atreca.com. Learn More about contacing Atreca investor relations.